Navigation Links
Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
Date:4/14/2009

y proven omega-3 phospholipids exhibiting unmatched safety, purity and stability. NKO(R) omega-3 marine phospholipids set a new standard of omega-3 excellence supported by a strong intellectual property portfolio and multinational regulatory approvals. Neptune pursues market opportunities in the nutraceutical markets (dietary supplement, functional food) and pharmaceutical markets (OTC, medical food, Rx) through its subsidiaries Acasti Pharma for cardiovascular applications and NeuroBioPharm for neurological applications.

    NASDAQ does not accept responsibility for the adequacy or accuracy of
    this press release. Neither TSX Venture Exchange nor its Regulation
    Services Provider (as that term is defined in the policies of the TSX
    Venture Exchange) accepts responsibility for the adequacy or accuracy of
    this release.

Statements in this press release that are not statements of historical or current fact, including statments relating to the Company's expectation regarding the future performance and marketability of its products, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates,"should," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the S
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... continuous operation up to 1500 bar. The sanitary design gauge of the NS2006L ... contamination. , The Pony™ NS2006L homogenizer is an ideal solution for the processing ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... UCT Specialties LLC is now,offering their new Product ... in research and development and with input from chemists ... years, each guide is,designed to illustrate and explain the ... it represents., With thousands of calls and monthly ...
... 12 General Research Laboratory,Inc. (GRL) and ... are,advancing their partnership initiated in July 2007 ... products, following the successful,identification of siRNA inhibitors ... of in silico and in vitro studies, ...
... Corporation,(Nasdaq: VOLC ), a leading provider of ... to enhance the diagnosis and,treatment of coronary and ... participating in the Cowen and Company 28th Annual ... presentation by Scott Huennekens, president and chief executive,officer, ...
Cached Biology Technology:UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 3Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 2
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... A first of its kind combination of experiment ... National Laboratory is providing a close-up look at the ... component of plant cell walls, aggregates to form clumps, ... The exact shape and structure of the aggregates, however, ...
... Palo Alto, CA Although scientists have been able to ... a context for associating the proteins encoded in genes ... underlying plant physiology and ecologyespecially in regard to photosynthesisa ... list of proteins encoded in the genomes of plants ...
... International Osteoporosis Foundation (IOF) in collaboration with the European ... burden of fractures in Europe has been vastly underestimated. ... and Sweden alone, an estimated 2.5 million new ... 280 fractures per hour. It also showed an astounding ...
Cached Biology News:ORNL neutrons, simulations reveal details of bioenergy barrier 2What makes a plant a plant? 2Landmark report reveals immense burden of osteoporotic fractures in Europe 2
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
... Immunogen: Synthetic peptide derived from the ... rat ZO-1. Specificity: Specific for the ... Reactivity: Human Dog Rat Mouse (positive ... frozen mouse liver heart blood vessel and ...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: